Genedrive Plc · LSE:GDR
Genedrive — Investor Presentation (September 2026)
20 slides from Genedrive's investor presentation, September 2026
Slide 1: Transforming patient outcomes through rapid pharmacogenetic testing
Transforming patient outcomes through rapid pharmacogenetic testing Dr Gino Miele, CEO genedrive plc (LSE: GDR) Russ Shaw, CFO Transforming Patient Outcomes
Slide 2: Disclaimer (1/2)
Disclaimer (1/2). NOT FOR PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF THAT JURISDICTION. This document, which comprises a presentation and the anticipated income for the year endi
Slide 3: Disclaimer (2/2)
Disclaimer (2/2). Any recipients of this presentation outside the UK should inform themselves of and observe any applicable legal or regulatory requirements in their jurisdiction and are treated as having represented that they are able to receive this presentation without contravention of any law or
Slide 4: genedrive in action
genedrive in action. Approximately Clopidogrel can be 90,000 babies each ineffective in 30-60% of patients and lead to worse year are admitted to patient outcomes Neonatal care in the UK 1 in every 300 - 500 of these babies are at risk of profound hearing loss due to antibiotics genedrive rapid gene
Slide 5: At a glance
At a glance. Rapid precision medicine positioned for scale 1 Commercial-stage medtech 2 Two CE-IVD certified products 3 Significant addressable markets UK pharmacogenetic testing company Two CE-IVD products developed with focused on time-critical decisions. NHS partners: MT-RNR1 ✓ Commercial-stage o
Slide 6: Unmet clinical need
Unmet clinical need. The right treatment starts with the right insight Individual DNA variations influence how patients respond 95% Traditional PGx testing is usually done in centralised In acute and emergency care settings, critical Patients need the right drug, at the right dose, at the of people
Slide 7: The solution
The solution. Rapid near-patient pharmacogenetics at the point of clinical decision making Delivers result in as little as 26 minutes Supports safer, more effective prescribing in acute and emergency care Already demonstrating real-world prevention impact Powered by MT-RNR1 ID Kit CYP2C19 ID Kit gen
Slide 8: The market opportunity
The market opportunity. Rapid Pharmacogenetic testing is moving into routine clinical care pathways Why now? CE-IVD ✓ NICE-supported implementation pathways recognising UK markets ✓ NHS focus on genomics, prevention and £26M ~£190M productivity p.a. £480M p.a. ✓ Strong health economic evidence Globa
Slide 9: Product positioning: MT-RNR1 ID Kit
Product positioning. MT-RNR1 ID Kit Preventing avoidable, lifelong hearing loss 1 in 300 Strong clinical and economic impact With MT-RNR1 Clinical need variant Value delivered (UK) • Around 1 in 300 - 500 people carry high-risk • Up to £20M p.a. cochlear implant costs avoided MT-RNR1 variant • Up to
Slide 10: Commercial progress – MT-RNR1
Commercial progress – MT-RNR1. Building momentum in the UK and internationally UK Europe, Middle East & Rest of World Current progress Current progress • PALOH-UK Patient Enrollment Completed with nearly 6,000 babies • Memorandum of Understanding with Saudi Arabian Ministry of Health tested across 1
Slide 11: Product positioning: CYP2C19 ID Kit
Product positioning. CYP2C19 ID Kit Enables the right antiplatelet first time 30% High value, immediate economic and clinical benefit May not respond to Clinical need clopidogrel Value delivered (UK) • 1/3rd of patients may not respond to clopidogrel • ~3000 recurrent strokes potentially prevented a
Slide 12: Commercial progress – CYP2C19
Commercial progress – CYP2C19. Strong UK validation supporting international expansion UK Europe, Middle East & Rest of World Current progress Commercial progress • CE-IVD certified & NICE recommended • Early commercial traction through distributors • NHS England implementation guide published • Eur
Slide 13: Political drivers
Political drivers. A favourable policy environment for preventative pharmacogenetic testing NHS 10-year plan Life Sciences sector plan Pre-market engagement notices From treatment to prevention Positioning the UK as a global leader Clear signals of intent to tender for enabled by transformative in l
Slide 14: Positioned for scale
Positioned for scale. High-value markets with clear clinical need, strong economic benefits & scalable global potential UK commercialisation Beyond the UK: Global expansion Repeatable business model Large, accessible market with strong policy UK validation and increasing penetration Scalable, asset-
Slide 15: Our journey
Our journey. Transforming patient outcomes through rapid pharmacogenetic testing From early concept to global impact Early concept Development Certification NICE UK market International & clinical & regulatory recommendations penetration expansion validation & NHS adoption & growth 2017 2026+ ✓ Visi
Slide 16: Key financials
Key financials. Strong revenue momentum. Capital-light. Path to profitability. Revenue Growth Total Income (£M) (£M) ~£3M ~£1.4M 1.6 FY26E INCOME CASH BALANCE at Total Income 30 June 2026 Strong (unaudited) ~£1.4M revenue growth 1.2 trajectory £1.00M 0.8 ~£0.35M ~40 MONTHLY CASH BURN FTEs £0.50M Ope
Slide 17: Investment case
Investment case. ✓ Year on year revenue growth ✓ Growing recurring consumables revenue opportunity ✓ Capital-light business model ✓ Expanding UK adoption and international distributor ~£450M partnerships Annual addressable market ✓ Current focus on UK, Europe & Middle East ~£26M UK market
Slide 18: Newsflow
Newsflow. Key catalysts to expect in this financial year 1 MT-RNR1 Business as usual progression in various UK trusts (existing PALOH-UK users) 2 MT-RNR1 Business case progression in various UK trusts (~20) 3 NICE MT-RNR1 Evidence Generation Submission (PALOH-UK), publication and NICE accelerated pa
Slide 19: Summary
Summary. Transforming patient outcomes. Delivering long-term value. UK medtech Clear near-term Products meet Strong Poised for Profound patient growth and mid-term clear unmet commercial scalable impact. Strong opportunity commercial clinical needs of strategy and growth economic value opportunity g
Slide 20: For further information
For further information. www.genedrive.com genedrive investor hub